Leuprorelin and Hormonal Suppression
For transgender people undergoing hormone therapy, the suppression of endogenous hormone production is essential to achieve the desired gender-affirming effects. Leuprorelin works by continuously stimulating the pituitary gland to release gonadotropins, which initially increases sex hormone levels, but with sustained use, ultimately leads to their suppression.
In transgender women (assigned male at birth), leuprorelin helps suppress testosterone production, facilitating the feminization process by reducing masculine secondary sexual characteristics such as body hair growth and muscle mass. Similarly, in transgender men (assigned female at birth), leuprorelin suppresses estrogen production, promoting masculinization by inhibiting breast development and menstrual cycling.
Facilitating Hormonal Transition
Leuprorelin's ability to effectively suppress endogenous hormone production lays the groundwork for successful hormonal transition in transgender individuals. By creating a hormonal environment consistent with the individual's gender identity, leuprorelin facilitates the development of secondary sexual characteristics congruent with the desired gender, enhancing gender affirmation and overall well-being.
Dosage and Administration
Leuprorelin is typically administered via subcutaneous injection, with dosages ranging from monthly to quarterly formulations, depending on the specific treatment protocol and individual response. Healthcare providers specializing in transgender care will tailor the dosage and frequency of administration to optimize hormone suppression while minimizing side effects.